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August 11, 2009:661–8n heart failure patients treated with either ultrafiltration or
iuretics to achieve equivalent fluid removal, sustained hemody-
amic and neurohormonal benefit occurred only in the ultrafiltra-
ion group. Compared with the diuretic group, patients treated
ith ultrafiltration had lower norepinephrine, plasma renin, and
ldosterone levels for up to 90 days. Lower RAAS activation was
ssociated with sustained improvement in objective measures of
unctional capacity. The rate of 14 to 15 ml/min for interstitial
uid mobilization was outlined still earlier by Fauchald and
auchald (4), as recently reviewed by Schrier (5).
The conclusions of Rogers et al. (6) about the impact of
iuretics and ultrafiltration on renal function might or might not
e verified in larger trials. However, we feel strongly that the
mportant outcomes in subsequent studies involving patients hos-
italized with heart failure remain focused on a reduction of
ardiovascular mortality and heart failure rehospitalizations, rather
han on the more specific end point of renal function. This is
here we propose that new tactics are needed.
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s it Myocarditis or
rrhythmogenic Right
entricular Cardiomyopathy?
ieroni et al. (1) conclude that right ventricular myocarditis
requently mimics arrhythmogenic right ventricular cardiomyopa-
hy (ARVC), and 3-dimensional electroanatomic mapping (guided
ndomyocardial biopsy is a tool that can differentiate the 2 entities,
uiding appropriate therapy. The gist of their message suggests chat these 2 entities are mutually exclusive, and in their cohort,
lectrocardiographic abnormalities, arrhythmias, right ventricular
tructural and functional abnormalities, Task Force criteria fulfill-
ent, a 3-dimensional voltage map, and inducible arrhythmias on
lectrophysiologic testing could not separate the wheat from the
haff. Some experts have suggested that a “hot phase” may
nterpolate periods of clinical quiescence, and the former may
resent as myocarditis or worsening ventricular arrhythmia (2). If
e were to acknowledge the possibility of this alternative hypoth-
sis, the findings may be interpreted differently. The 15 patients
ho were diagnosed with myocarditis may represent a hot phase,
nd although they did not have fibrofatty changes, they fulfilled
ask Force criteria, which are quite specific for the diagnosis of the
isease. These patients with myocarditis may represent an earlier
hase of the disease, and the observation that none of these
atients experienced arrhythmic events gives credence to this
ossibility. Genetic testing in this sample would have been highly
esirable even though it is not considered necessary for diagnosis
y the authors. We agree with the authors that a revision and
eappraisal of diagnostic criteria for ARVC is long overdue.
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yocarditis Mimicking
rrhythmogenic Right
entricular Cardiomyopathy
e have read with interest the paper by Pieroni et al. (1)
ddressing myocarditis as a common differential diagnosis to
rrhythmogenic right ventricular cardiomyopathy (ARVC).
mong 30 patients noninvasively fulfilling Task Force criteria (2)
or ARVC, they found that 15 patients actually had myocarditis
ased on 3-dimensional electroanatomic voltage mapping-guided
ndomyocardial biopsy. Voltage-guided biopsy is an elegant way of
btaining histological material from areas of the right ventricle
ith electrical signs of regional abnormalities and may facilitate the
iagnostic workup. However, we have the following questions/
oncerns about the study by Pieroni et al. (1):
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August 11, 2009:661–8. Myocardial inflammation. Numerous previous reports docu-
ment myocardial inflammation as a frequent finding (up to 80%
of patients) in ARVC (3,4). The authors report, surprisingly,
that none of their ARVC patients had accompanying inflam-
mation. Furthermore, the results are not consistent with a
recent report from another Italian group investigating autopsy
material and explanted hearts in geno-positive ARVC patients
(5). That study showed accompanying inflammatory infiltra-
tions in 10 of 10 patients and no evidence of an infective
etiopathogenesis (5). Have the authors considered the possibil-
ity that the inflammatory infiltrations seen in the “myocarditis”
group are part of the ARVC phenotype and that fibrofatty
replacements may occur later in the course of the disease? This
possible difference in disease development may also explain the
benign course seen in the group in the relatively short follow-up
period.
. Viral genome in the myocardium. Five of the 15 patients
classified as having myocarditis had the presence of viral
genome (parvo B19 virus in 3 cases, influenza virus in 2 cases)
in the myocardium documented by PCR. Different viruses may
persist in asymptomatic individuals without being pathogenic.
A recent report from Italy showed 12 of 19 asymptomatic
individuals had detectable parvo B19 deoxyribonucleic acid in
their myocardium (6). In addition, ARVC patients may have
increased susceptibility of having myocarditis as a secondary
phenomenon.
. Molecular genetics. No mutation screening of desmosomal
genes was performed. Given the lack of reference diagnostic
modality for ARVC, the frequency of desmosomal mutations in
both groups is highly relevant. A positive molecular genetics
finding in the “myocarditis” group would reclassify the patient
into the “ARVC” group.
Based on the abovementioned observations, the results pre-
ented by Pieroni et al. (1) should be confirmed in larger ARVC
ohorts with supplementary desmosomal mutation screening.
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iagnosis of Myocarditis
imicking Arrhythmogenic
ight Ventricular Cardiomyopathy
he Role of Endomyocardial Biopsy
uided by Electroanatomic Voltage Map
ieroni et al. (1) recently reported a 50% prevalence of right
entricular (RV) myocarditis in a cohort of 30 patients fulfilling
tandardized diagnostic criteria for arrhythmogenic right ventric-
lar cardiomyopathy (ARVC). The differential diagnosis between
yocarditis and ARVC was obtained by performing electroana-
omic mapping of the RV and then focusing, “for the first time,”
n endomyocardial biopsy (EMB) on selected pathological areas
haracterized by low-voltage potentials (electroanatomic mapping-
uided EMB). Adopting this “novel diagnostic technique,” Pieroni
t al. (1) significantly modified the initial ARVC diagnosis.
We would like to make some comments regarding this study
nd its results. First, to the best of our knowledge, this is not the
rst report describing the electroanatomic mapping-guided EMB
ince this “novel diagnostic technique” has already been exhaus-
ively described by our group (2,3). In particular, in 2008, we
ublished the first report (3) documenting the feasibility of RV
oltage mapping-guided EMB in a series of 16 consecutive
atients with clinical evidence or suspicion for ARVC.
Second, contrary to the findings reported by Pieroni et al. (1), in
ur study (3), we did not observe histological evidence of myocar-
itis in any of the 16 patients with clinical evidence or suspicion for
RVC, in whom a pathological RV voltage map was documented.
p to now, we have been performing EMB targeting RV low-
oltage areas in more than 40 patients with clinical evidence or
uspicion for ARVC, and we have never observed evidence of
ctive or borderline myocarditis according to the Dallas criteria.
ur findings, in agreement with the observations of Corrado et al.
4), seem logical: since myocarditis usually has a patchy distribu-
ion in the heart chambers, it is unlikely to produce solid
ransmural scars detectable as low-voltage areas with endocardial
lectroanatomic mapping.
Third, in the study of Pieroni et al. (1), the most frequently
nvolved RV regions (Table 2 of their study), in descending order,
ere the outflow tract (77%), the anterior free wall (50%), and the
osteroinferior wall (43%), whereas the RV apex and the septal
all were less frequently involved (13% and 3%, respectively).
oherently, the authors included in the article 2 RV voltage maps,
btained from representative patients with ARVC (Fig. 2D of
heir study) and myocarditis (Fig. 3D of their study), both showing
